Office of Regulatory Management

Economic Review Form

Agency name	Department of Medical Assistance Services		
Virginia Administrative	N/A		
Code (VAC) Chapter			
citation(s)			
VAC Chapter title(s)	N/A		
Action title	Podiatry Manual, All Chapters		
Date this document	1/9/2024		
prepared			
Regulatory Stage	Issuance of Guidance Document		
(including Issuance of			
Guidance Documents)			

Cost Benefit Analysis

Complete Tables 1a and 1b for all regulatory actions. You do not need to complete Table 1c if the regulatory action is required by state statute or federal statute or regulation and leaves no discretion in its implementation.

Table 1a should provide analysis for the regulatory approach you are taking. Table 1b should provide analysis for the approach of leaving the current regulations intact (i.e., no further change is implemented). Table 1c should provide analysis for at least one alternative approach. You should not limit yourself to one alternative, however, and can add additional charts as needed.

Report both direct and indirect costs and benefits that can be monetized in Boxes 1 and 2. Report direct and indirect costs and benefits that cannot be monetized in Box 4. See the ORM Regulatory Economic Analysis Manual for additional guidance.

Table 1a: Costs and Benefits of the Proposed Changes (Primary Option)

(1) Direct & Indirect Costs & Benefits (Monetized)	All of the text in the Podiatry Manual is being deleted. This manual text was very much out of date. It was reviewed carefully, and relevant portions have already been moved to the Practitioner Manual. There is no need to have a separate manual for this provider type.			
	The manual revisions remove outdated language. The benefits are that outdated language will be removed and that the correct, up-to-date text (that already appears in the Practitioner Manual) will provide clarity to the regulatory community. There are no costs associated with the changes.			
	Note: Although the Podiatry Manual is being eliminated, we did not include Chapters 1 & 3 as part of the review, because these chapters are 100% boilerplate and identical across all of DMAS' manuals. Therefore, they will continue to appear in all of DMAS' other provider manuals.			
(2) Present				
Monetized Values	Direct & Indirect Costs	Direct & Indirect Benefits		
	(a)	(b)		
(3) Net Monetized Benefit				
(4) Other Costs & Benefits (Non- Monetized)				
(5) Information Sources				
Table 1b: Costs and	Table 1b: Costs and Benefits under the Status Quo (No change to the regulation)			
(1) Direct & Indirect Costs & Benefits (Monetized)	Leaving these manual chapters in place would mean that outdated language continues to be available to providers.			
(2) Present	Dinast & Indinast Conta	Direct & Lading of Day of the		
Monetized Values	Direct & Indirect Costs (a)	Direct & Indirect Benefits (b)		
	(a)			
(3) Net Monetized Benefit				

(4) Other Costs &				
Benefits (Non-				
Monetized)				
(5) Information				
Sources				
Table 1c: Costs and	Benefits under Alternative	Approac	ch(es)	
(1) Direct &	There are no alternative app	proaches.		
Indirect Costs &				
Benefits				
(Monetized)				
(2) Present			0.7.11	
Monetized Values	Direct & Indirect Costs		& Indirect Benefits	
	(a)	(b)		
(3) Net Monetized				
Benefit				
(4) Other Costs &				
Benefits (Non-				
Monetized)				
(5) Information				
Sources				
Impact on Local Par	rtners			
				
	-	s. See Pa	rt 8 of the ORM Cost Impact	
Analysis Guidance for	Analysis Guidance for additional guidance.			
Table 2: Impact on Local Partners				
(1) Direct &	There is no impact on local partners.			
Indirect Costs & Benefits				
(Monetized)				
,	I T			
(2) Present Monetized Values	Direct & Indirect Costs		Direct & Indirect Benefits	
Monetized values	(a)		(b)	
	(a)		(0)	

(3) Other Costs & Benefits (Non- Monetized)	
(4) Assistance	
(5) Information Sources	

Impacts on Families

Use this chart to describe impacts on families. See Part 8 of the ORM Cost Impact Analysis Guidance for additional guidance.

Table 3: Impact on Families

(1) Direct & Indirect Costs & Benefits (Monetized)	There is no impact on families.	
(2) Present Monetized Values	Direct & Indirect Costs (a)	Direct & Indirect Benefits (b)
(3) Other Costs & Benefits (Non- Monetized)		
(4) Information Sources		

Impacts on Small Businesses

Use this chart to describe impacts on small businesses. See Part 8 of the ORM Cost Impact Analysis Guidance for additional guidance.

Table 4: Impact on Small Businesses

There is no impact on small businesses.

(2) Present		
Monetized Values	Direct & Indirect Costs	Direct & Indirect Benefits
	(a)	(b)
(3) Other Costs &		
Benefits (Non-		
Monetized)		
(4) Alternatives		
(5) Information		
Sources		

Changes to Number of Regulatory Requirements

Table 5: Regulatory Reduction

Length of Guidance Documents (only applicable if guidance document is being revised)

Title of Guidance	Original Length	New Length	Net Change in
Document			Length
Podiatry Manual,	6,938	0	- 6,938
Chapter 2			
Podiatry Manual,	4,196	0	- 4,196
Chapter 4			
Podiatry Manual,	6,725	0	- 6,725
Chapter 5			
Podiatry Manual,	1,557	0	- 1,557
Chapter 6			
Podiatry Manual,	289	0	- 289
Appendix B			